Inhibition principles of the SARS-CoV-2 proteases | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Start & end year
2021
2023
Known Financial Commitments (USD)
$474,643.04
Funder
FWF
Research Location
Austria
Lead Research Institution
Sektion für Virologie, Medizinische Universität Innsbruck
Research Priority Alignment
N/A

Research Category
Therapeutics research, development and implementation
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

1 Publication linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

SARS-CoV-2 3CL^pro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376.